Bedaquiline and delamanid combination for drug-resistant TB: The Lancet Infectious Diseases: February 13, 2018
The Lancet Infectious Diseases in conversation with - Un pódcast de The Lancet Group
Categorías:
Amir Shroufi discusses the early results assessing the safety and efficacy of the combination of bedaquiline and delamanid against drug-resistant tuberculosis.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
